Lv41
462 积分 2022-09-19 加入
Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy
7小时前
已完结
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
8天前
已完结
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
8天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
11天前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
11天前
已完结
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial
18天前
已完结
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
1个月前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
2个月前
已完结
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
2个月前
已完结
皖公网安备34019202002308
